Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;113(4):803-815.
doi: 10.1002/cpt.2711. Epub 2022 Jul 31.

Pharmacogenomic Clinical Decision Support: A Scoping Review

D Max Smith  1   2 , Dyson T Wake  3 , Henry M Dunnenberger  3
Affiliations

Pharmacogenomic Clinical Decision Support: A Scoping Review

D Max Smith et al. Clin Pharmacol Ther. 2023 Apr.

Abstract

Clinical decision support (CDS) is often cited as an essential part of pharmacogenomics (PGx) implementations. A multitude of strategies are available; however, it is unclear which strategies are effective and which metrics are used to quantify clinical utility. The objective of this scoping review was to aggregate previous studies into a cohesive depiction of the current state of PGx CDS implementations and identify areas for future research on PGx CDS. Articles were included if they (i) described electronic CDS tools for PGx and (ii) reported metrics related to PGx CDS. Twenty of 3,449 articles were included and provided data on PGx CDS metrics from 15 institutions, with 93% of programs located at academic medical centers. The most common tools in CDS implementations were interruptive post-test alerts. Metrics for clinical response and alert response ranged from 12-73% and 21-98%, respectively. Few data were found on changes in metrics over time and measures that drove the evolution of CDS systems. Relatively few data were available regarding support of optimal approaches for PGx CDS. Post-test alerts were the most widely studied approach, and their effectiveness varied greatly. Further research on the usability, effectiveness, and optimization of CDS tools is needed.

PubMed Disclaimer

References

    1. Roden, D.M. et al. Pharmacogenomics. Lancet 394, 521-532 (2019).
    1. Empey, P.E., Pratt, V.M., Hoffman, J.M., Caudle, K.E. & Klein, T.E. Expanding evidence leads to new pharmacogenomics payer coverage. Genet. Med. 23, 830-832 (2021).
    1. Denny, J.C. & Collins, F.S. Precision medicine in 2030-seven ways to transform healthcare. Cell 184, 1415-1419 (2021).
    1. U.S. Food and Drug Administration. Table of pharmacogenomic associations <https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogen.... Accessed September 13, 2021.
    1. Relling, M.V., Klein, T.E., Gammal, R.S., Whirl-Carrillo, M., Hoffman, J.M. & Caudle, K.E. The clinical pharmacogenetics implementation consortium: 10 years later. Clin. Pharmacol. Ther. 107, 171-175 (2020).

Publication types

LinkOut - more resources